The attached document contains a new Request for Proposal (RFP) from Pfizer's Global Medical Grants program. While Pfizer recognizes many institutions and healthcare professionals around the globe are prioritizing challenges associated with the COVID-19 pandemic, we are cognizant that the healthcare and patient community will continue to benefit from ongoing support for research, improvement science, and education in spite of this crisis. It is in this spirit that Pfizer will continue our grants program by publishing RFPs that have been planned for 2020.

Thank you in advance for all that you are doing to improve the care of patients. Pfizer is proud to be able to support these efforts through this grants program.

Please contact the Global Medical Grants team at GMG@pfizer.com if you have any questions or would like to be temporarily removed from our mailing list.

PFIZER

Pfizer Announces

Artificial Intelligence/Machine Learning Research in Hemophilia

Competitive Grant Program- using Expert Review Panel

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Competitive Grant Program Eligibility

Geographic Scope	• United States
Applicant Eligibility Criteria	To be eligible: • The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • Applicant must be affiliated with a host institution

Requirements

Date RFP Issued	• April 20, 2020
Clinical Area	• Hemophilia
Area of Interest Focus	Projects that will be considered for Pfizer support will focus on Artificial Intelligence/Machine Learning in the areas mentioned below. Projects with a focus on emerging potential one-time treatments such as genetic medicine/gene transfer will be preferentially considered. • Research studies that develop artificial intelligence/machine learning methods, tools and/or apps to use patient data on, for example, infusions, bleeds, laboratory factors and lifestyle to assist clinicians in treatment selection o a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred • Research studies that develop AI/ML methods and tools to increase the ability to predict disease risk; identify disease severity and progression due to morbidity from joint disease or recurrent bleeding; and/or improve disease management for persons with hemophilia (PWH) including optimizing treatment for patients with high bleeding risk (e.g., severe hemophilia) • Research projects that develop AI/ML methods and tools to enhance patient engagement with the local hemophilia treatment center and maximize follow-up after potential one-time treatments such as gene therapy, including for patients living in remote or geographically distant areas

	• Research projects that develop intelligent educational tools and platforms, leveraging AI/ML to deliver innovative educational and training programs for patients, caregivers, clinicians, healthcare providers, researchers, regulatory agencies and policy makers to increase knowledge sharing, awareness and advocacy for hemophilia o a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred • Research studies that leverage AI/ML to enhance data surveillance and increase collaboration among data partners and the ability to collect PWH-related data in real time and to link useful real world data from diverse sources (e.g., claims, EHR, registry, patient-reported outcomes, patient-level channels such as wearable devices, mobile apps, sensors) to advance the understanding of hemophilia disease progression, treatment outcomes, factors influencing prognosis and quality of life, evidence on resource utilization, etc. • Develop a recommendation system leveraging AI-NLP approach and published literature and scientific evidence to offer more personalized guidelines and algorithms to monitor adherence and outcomes.
Expected Approximate Monetary Range of Grant Applications	• Individual projects requesting up to $350,000-450,000 will be considered. Pfizer anticipates awarding up to 1 grant • The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel's evaluation of the proposal and costs involved, and will be stated clearly in the approval notification
Key Dates	• RFP release date: April 20, 2020 • Proposal Deadline: *September 10, 2020 **[Deadline Extended]** *Please note the deadline is 23:59 Eastern Time (New York, GMT -5). • Review of Full Proposals by ERP: September 2020 • Anticipated Full Proposal Notification Date: October 2020 • If approved, agreement must be signed by December 2020
How to Apply	• Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click "Create your password". Requirements for submission: • Select the following Competitive Grant Program Name: 2020 RD L-Artificial Intelligence/Machine Learning in Hemophilia • Complete all required sections of the online application. See Appendix A for additional details • If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page

Questions:	• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com), with the subject line "Artificial Intelligence/Machine Learning in Hemophilia." • Please click here to view Frequently Asked Questions regarding the Competitive Grant Program
Review and Approval Process	• Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions. • The panels are comprised of professionals with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement
Mechanism by which Applicants will be Notified:	• All applicants will be notified via email by the dates noted above • Applicants may be asked for additional clarification during the review period

Appendix A
Full Proposal/Protocol

Applications will be accepted via the online portal. Full Proposal/Protocol documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal/Protocol please ensure it addresses the following:

Goals and Objectives	• Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective
Assessment of Need for the Project	• This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question
Target Audience	• Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population • Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
Project Design and Methods	• Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan
Innovation	• Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project
Evaluation and Outcomes	• Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures • Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines
Anticipated Project Timeline	• Provide an anticipated timeline for your project including project start/end dates
Additional Information	• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here • Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's

	career.
Organization Detail	• This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project
References	• Bibliography of relevant references.